Skip to content
Droperidol
Inapsine, Innovar (droperidol) is a small molecule pharmaceutical. Droperidol was first approved as Inapsine on 1982-01-01. It is used to treat pain and psychotic disorders in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
psychological phenomenaD011579
mental disordersD001523
musculoskeletal and neural physiological phenomenaD055687
Trade Name
FDA
EMA
Inapsine (generic drugs available since 1988-02-29)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Droperidol
Tradename
Company
Number
Date
Products
INAPSINEAkornN-016796 RX1982-01-01
1 products, RLD, RS
Droperidol
+
Fentanyl citrate
Tradename
Company
Number
Date
Products
INNOVARAkornN-016049 DISCN1982-01-01
1 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
droperidolANDA2019-10-29
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
painEFO_0003843D010146R52
psychotic disorders—D011618F20.81
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N05: Psycholeptics
— N05A: Antipsychotics
— N05AD: Butyrophenone derivatives, antipsychotics
— N05AD08: Droperidol
HCPCS
Code
Description
J1790
Injection, droperidol, up to 5 mg
J1810
Injection, droperidol and fentanyl citrate, up to 2 ml ampule
Clinical
Clinical Trials
316 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Acne vulgarisD000152EFO_0003894L703648119
RosaceaD012393L713148117
Covid-19D000086382U07.11353213
InfectionsD007239EFO_0000544———6410
Periodontal diseasesD010510K05.6—32239
Chlamydia infectionsD002690EFO_0007205A74.9—125—8
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9——2316
SyphilisD013587EFO_0007504A53.9——24—6
Lyme diseaseD008193A69.2——2215
Erythema chronicum migransD015787A26.0———145
Show 51 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AmyloidosisD000686EFO_1001875E85131—14
Chronic periodontitisD055113EFO_0006343K05.3—32——4
Graves ophthalmopathyD049970EFO_1001466131—14
Filarial elephantiasisD004605EFO_0007272B74.0——3——3
LymphedemaD008209Q82.0——3——3
FilariasisD005368B74——3——3
TuberculosisD014376EFO_0000774A15-A19—21——3
Heart failureD006333EFO_0003144I50—11——2
Ventricular remodelingD020257—11——2
St elevation myocardial infarctionD000072657—11——2
Show 22 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179—2——13
Ulcerative colitisD003093EFO_0000729K51—2——13
Pelvic inflammatory diseaseD000292EFO_1001388N70-N77—1——12
Non-small-cell lung carcinomaD002289—1——12
AnthraxD000881A2211———2
Pancreatic neoplasmsD010190EFO_0003860C25—1——12
Breast neoplasmsD001943EFO_0003869C5011———2
T-cell lymphoma cutaneousD016410C84.A11———2
Atopic dermatitisD003876EFO_0000274L20—2———2
MansonelliasisD008368EFO_0007357B74.4—2———2
Show 57 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—6———28
Therapeutic equivalencyD0138105————5
Tennis elbowD013716EFO_1001896M77.11———12
Arteriovenous malformationsD0011652————2
Elbow tendinopathyD000070639M77.01————1
Coronavirus infectionsD018352EFO_0007224B34.21————1
Severe acute respiratory syndrome-related coronavirusD045473NCBITaxon_2278591————1
Cardio-renal syndromeD0593471————1
Intracranial aneurysmD002532EFO_0003870I67.11————1
Cavernous hemangiomaD006392D18.01————1
Show 6 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Tick-borne encephalitisD004675EFO_1001309A84————22
Rheumatoid arthritisD001172EFO_0000685M06.9————22
MalariaD008288EFO_0001068B54————11
Mycoplasma pneumoniaD011019EFO_0007387J15.7————11
Aseptic meningitisD008582EFO_1000823G03.0————11
Staphylococcus aureusD013211NCBITaxon_1280————11
Female infertilityD007247EFO_0008560N97————11
Liver cirrhosisD008103EFO_0001422K74.0————11
InfertilityD007246EFO_0000545————11
Diet therapyD004035————11
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDROPERIDOL
INNdroperidol
Description
Droperidol is an organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It has a role as an antiemetic, a dopaminergic antagonist, a first generation antipsychotic and an anaesthesia adjuvant. It is a member of benzimidazoles, an organofluorine compound and an aromatic ketone.
Classification
Small molecule
Drug classantipsychotics (haloperidol type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O=C(CCCN1CC=C(n2c(=O)[nH]c3ccccc32)CC1)c1ccc(F)cc1
Identifiers
PDB—
CAS-ID548-73-2
RxCUI3648
ChEMBL IDCHEMBL1108
ChEBI ID4717
PubChem CID3168
DrugBankDB00450
UNII IDO9U0F09D5X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,048 documents
View more details
Safety
Black-box Warning
Black-box warning for: Droperidol
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
21,334 adverse events reported
View more details